{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:30:31Z","timestamp":1791689431697,"version":"4.3.4"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.lfs.2022.120956","type":"journal-article","created":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T17:44:59Z","timestamp":1662918299000},"page":"120956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms"],"prefix":"10.1016","volume":"308","author":[{"given":"Hager H.","family":"Shaaban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Alzaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El-Mallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania G.","family":"Aly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-3038","authenticated-orcid":false,"given":"Ahmed F.","family":"El-Yazbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Wahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0005","doi-asserted-by":"crossref","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.lfs.2022.120956_bb0010","first-page":"201","article-title":"Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome","volume":"57","author":"Uchil","year":"2009","journal-title":"J. Assoc. Physicians India"},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: pathogenesis and disease spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu. Rev. Pathol.: Mech. Dis."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3892\/etm.2013.1090","article-title":"Association between metabolic syndrome and the development of non-alcoholic fatty liver disease","volume":"6","author":"Wang","year":"2013","journal-title":"Exp. Ther. Med.1"},{"issue":"8","key":"10.1016\/j.lfs.2022.120956_bb0025","first-page":"74","article-title":"Insulin resistance and NAFLD: a dangerous liaison beyond the genetics","volume":"4","author":"Manco","year":"2017","journal-title":"Children (Basel)"},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cld.2017.08.007","article-title":"Pathophysiology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"22","author":"Manne","year":"2018","journal-title":"Clin. Liver Dis."},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0035","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.lfs.2022.120956_bb0040","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1381\/096089202320995592","article-title":"Liver damage in obese patients","volume":"12","author":"Del Gaudio","year":"2002","journal-title":"Obes. Surg."},{"issue":"5","key":"10.1016\/j.lfs.2022.120956_bb0045","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3748\/wjg.v9.i5.1106","article-title":"Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey","volume":"9","author":"Shen","year":"2003","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120956_bb0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-132-2-200001180-00004","article-title":"Prevalence of and risk factors for hepatic steatosis in northern Italy","volume":"132","author":"Bellentani","year":"2000","journal-title":"Ann. Intern. Med."},{"issue":"27","key":"10.1016\/j.lfs.2022.120956_bb0055","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","article-title":"Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \"two hit theory\" to \"multiple hit model\"","volume":"24","author":"Fang","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.lfs.2022.120956_bb0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0939-4753(04)80048-6","article-title":"The metabolic syndrome and inflammation: association or causation?","volume":"14","author":"Esposito","year":"2004","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0065","first-page":"9","article-title":"Non alcoholic fatty liver disease and metabolic syndrome","volume":"13","author":"Paschos","year":"2009","journal-title":"Hippokratia"},{"issue":"7","key":"10.1016\/j.lfs.2022.120956_bb0070","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1042\/CS20190227","article-title":"Targeting perivascular and epicardial adipose tissue inflammation: therapeutic opportunities for cardiovascular disease","volume":"134","author":"Rafeh","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.lfs.2022.120956_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.602088","article-title":"Adipose tissue immunomodulation: a novel therapeutic approach in cardiovascular and metabolic diseases","volume":"7","author":"AlZaim","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.lfs.2022.120956_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.626313","article-title":"Modulatory effect of intermittent fasting on adipose tissue inflammation: amelioration of cardiovascular dysfunction in early metabolic impairment","volume":"12","author":"Dwaib","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1124\/molpharm.121.000338","article-title":"Sex differences in cardiovascular impact of early metabolic impairment: interplay between dysbiosis and adipose inflammation","volume":"102","author":"Dwaib","year":"2022","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.lfs.2022.120956_bb0090","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.lfs.2022.120956_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ph11040121","article-title":"Antidiabetic drugs in NAFLD: the accomplishment of two goals at once?","volume":"11","author":"Tacelli","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3803\/EnM.2018.33.3.387","article-title":"Effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non-alcoholic fatty liver disease","volume":"33","author":"Choi","year":"2018","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2022.120956_bb0105","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211000243","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data","volume":"12","author":"Arai","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2022.120956_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.613389","article-title":"Sodium-glucose Cotransporter-2 inhibitors ameliorate liver enzyme abnormalities in Korean patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Euh","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.lfs.2022.120956_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10741-017-9665-9","article-title":"Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects","volume":"23","author":"Kaplan","year":"2018","journal-title":"Heart Fail. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4254\/wjh.v6.i3.144","article-title":"Hepatoprotective effect of silymarin","volume":"6","author":"Vargas-Mendoza","year":"2014","journal-title":"World J. Hepatol."},{"issue":"5","key":"10.1016\/j.lfs.2022.120956_bb0130","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.21874","article-title":"Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet","volume":"46","author":"Matsuzawa","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0135","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/jmf.2013.0179","article-title":"Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl4-treated rats","volume":"18","author":"Clichici","year":"2014","journal-title":"J. Med. Food"},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5114\/ceh.2019.83159","article-title":"Allopurinol potentiates the hepatoprotective effect of metformin and vitamin E in fructose-induced fatty liver in rats","volume":"5","author":"Khalaf","year":"2019","journal-title":"Clin. Exp. Hepatol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0145","first-page":"67","article-title":"Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis","volume":"65","author":"Surapaneni","year":"2014","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.lfs.2022.120956_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106730","article-title":"Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-\u03b1, IL-1\u03b2, and IL-18 in rat liver","volume":"86","author":"ElMahdy","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120956_bb0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/0976-500X.72350","article-title":"Blood sample collection in small laboratory animals","volume":"1","author":"Parasuraman","year":"2010","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"7","key":"10.1016\/j.lfs.2022.120956_bb0160","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2022.120956_bb0165","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.toxrep.2015.01.001","article-title":"Histopathological and biochemical assessment of d-limonene-induced liver injury in rats","volume":"2","author":"Ramos","year":"2015","journal-title":"Toxicol. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0003-2697(78)90342-1","article-title":"Determination of malonaldehyde precursor in tissues by thiobarbituric acid test","volume":"86","author":"Mihara","year":"1978","journal-title":"Anal. Biochem."},{"issue":"3\u20135","key":"10.1016\/j.lfs.2022.120956_bb0175","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0171-2985(11)80347-5","article-title":"Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6","volume":"187","author":"Brouckaert","year":"1993","journal-title":"Immunobiology"},{"issue":"9","key":"10.1016\/j.lfs.2022.120956_bb0180","first-page":"1037","article-title":"Evaluation of bax, bcl-2, p21 and p53 genes expression variations on cerebellum of BALB\/c mice before and after birth under mobile phone radiation exposure","volume":"20","author":"Ghatei","year":"2017","journal-title":"Iran. J. Basic Med. Sci."},{"issue":"8","key":"10.1016\/j.lfs.2022.120956_bb0185","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2016.01.025","article-title":"Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?","volume":"150","author":"Gao","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.lfs.2022.120956_bb0190","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.lfs.2022.120956_bb0195","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.lfs.2022.120956_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: state of art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.lfs.2022.120956_bb0205","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/00365520701514529","article-title":"Non-alcoholic fatty liver disease","volume":"42","author":"Bj\u00f6rnsson","year":"2007","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2022.120956_bb0210","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH","volume":"26","author":"Raza","year":"2021","journal-title":"Front. Biosci."},{"issue":"17","key":"10.1016\/j.lfs.2022.120956_bb0215","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2174\/138161210791208875","article-title":"Insulin resistance in nonalcoholic fatty liver disease","volume":"16","author":"Bugianesi","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"44","key":"10.1016\/j.lfs.2022.120956_bb0220","doi-asserted-by":"crossref","first-page":"42774","DOI":"10.1074\/jbc.M306022200","article-title":"Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression","volume":"278","author":"Vergnes","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.lfs.2022.120956_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152599","article-title":"Dietary fat, cholesterol, and cholic acid affect the histopathologic severity of nonalcoholic steatohepatitis in Sprague-dawley rats","volume":"215","author":"Fukuda","year":"2019","journal-title":"Pathol. Res. Pract."},{"issue":"2","key":"10.1016\/j.lfs.2022.120956_bb0230","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.22363","article-title":"Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis","volume":"48","author":"Wouters","year":"2008","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"10.1016\/j.lfs.2022.120956_bb0235","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00394-012-0459-5","article-title":"An atherogenic diet decreases liver FXR gene expression and causes severe hepatic steatosis and hepatic cholesterol accumulation: effect of endurance training","volume":"52","author":"C\u00f4t\u00e9","year":"2013","journal-title":"Eur. J. Nutr."},{"issue":"10","key":"10.1016\/j.lfs.2022.120956_bb0240","article-title":"Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.lfs.2022.120956_bb0245","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1007\/s10620-013-2775-x","article-title":"Betaine protects against high-fat-diet-induced liver injury by inhibition of high-mobility group box 1 and toll-like receptor 4 expression in rats","volume":"58","author":"Zhang","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.lfs.2022.120956_bb0250","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10620-009-0815-3","article-title":"Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats","volume":"55","author":"Xu","year":"2010","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0255","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12986-019-0410-3","article-title":"Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE\u2212\/\u2212 mice by improving intestinal barrier function and reducing endotoxin and liver TLR4\/NF-\u03baB inflammation","volume":"16","author":"Feng","year":"2019","journal-title":"Nutr. Metab."},{"issue":"2","key":"10.1016\/j.lfs.2022.120956_bb0260","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2008.01.004","article-title":"Balancing cholesterol synthesis and absorption in the gastrointestinal tract","volume":"2","author":"Cohen","year":"2008","journal-title":"J. Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.lfs.2022.120956_bb0265","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","author":"de Aguiar Vallim","year":"2013","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.lfs.2022.120956_bb0270","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.lfs.2022.120956_bb0275","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1124\/dmd.110.035006","article-title":"Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease","volume":"38","author":"Hardwick","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"15\u201316","key":"10.1016\/j.lfs.2022.120956_bb0280","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.cca.2011.04.013","article-title":"The role of oxidative stress in non-alcoholic steatohepatitis","volume":"412","author":"Koek","year":"2011","journal-title":"Clin. Chim. Acta"},{"issue":"11","key":"10.1016\/j.lfs.2022.120956_bb0285","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bcp.2006.04.011","article-title":"NF-kappaB activation by reactive oxygen species: fifteen years later","volume":"72","author":"Gloire","year":"2006","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WOX.0b013e3182439613","article-title":"Oxidative stress and antioxidant defense","volume":"5","author":"Birben","year":"2012","journal-title":"World Allergy Organ J."},{"key":"10.1016\/j.lfs.2022.120956_bb0295","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.redox.2015.01.002","article-title":"Oxidative stress: a concept in redox biology and medicine","volume":"4","author":"Sies","year":"2015","journal-title":"Redox Biol."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2022.120956_bb0300","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cccn.2004.12.022","article-title":"Glutathione metabolism and antioxidant enzymes in patients affected by nonalcoholic steatohepatitis","volume":"355","author":"Nobili","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.lfs.2022.120956_bb0305","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2768365","article-title":"Oxidative stress related diseases in newborns","volume":"2016","author":"Ozsurekci","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0310","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cmet.2006.07.006","article-title":"Mitochondrial free cholesterol loading sensitizes to TNF- and fas-mediated steatohepatitis","volume":"4","author":"Mar\u00ed","year":"2006","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.lfs.2022.120956_bb0315","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.lfs.2022.120956_bb0320","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.lfs.2022.120956_bb0325","doi-asserted-by":"crossref","first-page":"G1281","DOI":"10.1152\/ajpgi.00074.2008","article-title":"Gene expression in human NAFLD","volume":"294","author":"Greco","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"6","key":"10.1016\/j.lfs.2022.120956_bb0330","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/jhep.2001.29628","article-title":"Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients","volume":"34","author":"Crespo","year":"2001","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.lfs.2022.120956_bb0335","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.22363","article-title":"Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis","volume":"48","author":"Wouters","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.lfs.2022.120956_bb0340","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.bbrc.2005.12.109","article-title":"Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice","volume":"340","author":"Tous","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.lfs.2022.120956_bb0345","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00535-006-1883-1","article-title":"Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis","volume":"41","author":"Kainuma","year":"2006","journal-title":"J. Gastroenterol."},{"issue":"23","key":"10.1016\/j.lfs.2022.120956_bb0350","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/CIRCULATIONAHA.104.506188","article-title":"Cholesterol feeding increases C-reactive protein and serum amyloid a levels in lean insulin-sensitive subjects","volume":"111","author":"Tannock","year":"2005","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.lfs.2022.120956_bb0355","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0360","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.gastro.2011.09.049","article-title":"A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells","volume":"142","author":"Teratani","year":"2012","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.lfs.2022.120956_bb0365","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.lfs.2022.120956_bb0370","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1053\/j.gastro.2008.03.002","article-title":"Cellular and molecular mechanisms of liver injury","volume":"134","author":"Malhi","year":"2008","journal-title":"Gastroenterology"},{"issue":"53","key":"10.1016\/j.lfs.2022.120956_bb0375","doi-asserted-by":"crossref","first-page":"8608","DOI":"10.1038\/sj.onc.1207108","article-title":"Regulation of apoptosis by endoplasmic reticulum pathways","volume":"22","author":"Breckenridge","year":"2003","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.lfs.2022.120956_bb0380","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/ncb1035","article-title":"The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages","volume":"5","author":"Feng","year":"2003","journal-title":"Nat. Cell Biol."},{"issue":"36","key":"10.1016\/j.lfs.2022.120956_bb0385","doi-asserted-by":"crossref","first-page":"33928","DOI":"10.1074\/jbc.M210943200","article-title":"Cholesterol impairs the adenine nucleotide translocator-mediated mitochondrial permeability transition through altered membrane fluidity","volume":"278","author":"Colell","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0390","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/gast.2003.50089","article-title":"Acetaldehyde impairs mitochondrial glutathione transport in HepG2 cells through endoplasmic reticulum stress","volume":"124","author":"Lluis","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.lfs.2022.120956_bb0395","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s12325-020-01251-y","article-title":"Silymarin as supportive treatment in liver diseases: a narrative review","volume":"37","author":"Gillessen","year":"2020","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.lfs.2022.120956_bb0400","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1572-0241.1998.00139.x","article-title":"Milk thistle (Silybum marianum) for the therapy of liver disease","volume":"93","author":"Flora","year":"1998","journal-title":"Am. J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.lfs.2022.120956_bb0405","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/0006-2952(90)90625-U","article-title":"Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant","volume":"39","author":"Lett\u00e9ron","year":"1990","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0410","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.fct.2009.12.011","article-title":"Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage","volume":"48","author":"Shaker","year":"2010","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.lfs.2022.120956_bb0415","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/gut.2006.091967","article-title":"A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations","volume":"55","author":"Federico","year":"2006","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0420","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4254\/wjh.v5.i3.109","article-title":"Silymarin in non alcoholic fatty liver disease","volume":"5","author":"Cacciapuoti","year":"2013","journal-title":"World J. Hepatol."},{"issue":"4","key":"10.1016\/j.lfs.2022.120956_bb0425","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2009.03.016","article-title":"Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein","volume":"137","author":"He","year":"2009","journal-title":"Cell"},{"issue":"38","key":"10.1016\/j.lfs.2022.120956_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15380","article-title":"Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review","volume":"15","author":"Shyangdan","year":"2011","journal-title":"Health Technol. Assess."},{"issue":"6","key":"10.1016\/j.lfs.2022.120956_bb0435","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1024\/0300-9831\/a000086","article-title":"Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver","volume":"81","author":"Akcam","year":"2011","journal-title":"Int. J. Vitam. Nutr. Res."},{"issue":"10","key":"10.1016\/j.lfs.2022.120956_bb0440","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2010.04467.x","article-title":"Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis","volume":"32","author":"Rakoski","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.lfs.2022.120956_bb0445","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","article-title":"Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis","volume":"29","author":"Loomba","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0450","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/MCB.06159-11","article-title":"Role of AMPK-mTOR-Ulk1\/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks","volume":"32","author":"Alers","year":"2012","journal-title":"Mol. Cell. Biol."},{"issue":"10","key":"10.1016\/j.lfs.2022.120956_bb0455","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/oby.20846","article-title":"\u03b1-lipoic acid reduces fatty acid esterification and lipogenesis in adipocytes from overweight\/obese subjects","volume":"22","author":"Fern\u00e1ndez-Galilea","year":"2014","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0460","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10787-022-00980-6","article-title":"The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases","volume":"30","author":"Hasanvand","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"7","key":"10.1016\/j.lfs.2022.120956_bb0465","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00109-011-0748-0","article-title":"AMP-activated protein kinase inhibits NF-\u03baB signaling and inflammation: impact on healthspan and lifespan","volume":"89","author":"Salminen","year":"2011","journal-title":"J. Mol. Med. (Berl)"},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0470","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1210\/jc.2003-031315","article-title":"Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients","volume":"89","author":"Bajaj","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.lfs.2022.120956_bb0475","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/diabetes.53.8.2169","article-title":"Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes","volume":"53","author":"Tiikkainen","year":"2004","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.lfs.2022.120956_bb0480","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1055\/s-2005-870320","article-title":"Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control","volume":"37","author":"Pf\u00fctzner","year":"2005","journal-title":"Horm. Metab. Res."},{"issue":"2","key":"10.1016\/j.lfs.2022.120956_bb0485","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbrc.2003.12.120","article-title":"Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo","volume":"314","author":"Saha","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.lfs.2022.120956_bb0490","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm788","article-title":"Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase","volume":"8","author":"Yamauchi","year":"2002","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.lfs.2022.120956_bb0495","doi-asserted-by":"crossref","first-page":"G526","DOI":"10.1152\/ajpgi.00243.2015","article-title":"Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice","volume":"310","author":"van der Veen","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"4","key":"10.1016\/j.lfs.2022.120956_bb0500","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3233\/CBM-170157","article-title":"Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: evidence from in vitro study","volume":"20","author":"Deng","year":"2017","journal-title":"Cancer Biomark."},{"issue":"2","key":"10.1016\/j.lfs.2022.120956_bb0505","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes. Obes. Metab."},{"issue":"7","key":"10.1016\/j.lfs.2022.120956_bb0510","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/jphp.12223","article-title":"Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats","volume":"66","author":"Tahara","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2022.120956_bb0515","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120956_bb0520","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jceh.2015.02.005","article-title":"Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice","volume":"5","author":"Nakano","year":"2015","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146337","article-title":"The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2022.120956_bb0530","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13098-015-0102-8","article-title":"Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus","volume":"7","author":"Qiang","year":"2015","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.lfs.2022.120956_bb0535","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.lfs.2022.120956_bb0540","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","article-title":"Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study","volume":"87","author":"Tobita","year":"2017","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.lfs.2022.120956_bb0545","first-page":"1190","article-title":"Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120956_bb0550","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.lfs.2022.120956_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106730","article-title":"Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-\u03b1, IL-1\u03b2, and IL-18 in rat liver","volume":"86","author":"ElMahdy","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.lfs.2022.120956_bb0560","article-title":"Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases","volume":"10","author":"Tsai","year":"2021","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"5","key":"10.1016\/j.lfs.2022.120956_bb0565","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep4.1611","article-title":"Impact of sodium glucose cotransporter 2 inhibitors on nonalcoholic fatty liver disease complicated by diabetes mellitus","volume":"5","author":"Zhang","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.lfs.2022.120956_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114491","article-title":"Peri-renal adipose inflammation contributes to renal dysfunction in a non-obese prediabetic rat model: role of anti-diabetic drugs","volume":"186","author":"Hammoud","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2022.120956_bb0575","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trsl.2019.07.009","article-title":"Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs","volume":"214","author":"Elkhatib","year":"2019","journal-title":"Transl. Res."},{"issue":"18","key":"10.1016\/j.lfs.2022.120956_bb0580","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522006567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522006567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:04:43Z","timestamp":1758402283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522006567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":116,"alternative-id":["S0024320522006567"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120956","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120956"}}